Mohsen Janghorbani1, Hoseinali Adineh2, Masoud Amini1. 1. Isfahan Endocrine and Metabolism Research Center, Isfahan University of Medical Sciences, Isfahan, Iran. 2. Department of Epidemiology and Biostatistics, School of Public Health, Isfahan University of Medical Sciences, Isfahan, Iran.
Abstract
OBJECTIVES: Traditionally, the Finnish Diabetes Risk Score (FINDRISC) questionnaire is a screening tool to estimate risk of type 2 diabetes. In this study, we evaluated the ability of FINDRISC to predict the development of the metabolic syndrome (MetS) in an Iranian population without diabetes and MetS. METHODS: A total of 1,010 first-degree relatives of consecutive patients with type 2 diabetes, 30-70 years old (274 men and 736 women), without diabetes and MetS, were examined and followed up over 8.0 ± 1.6 years (mean ± SD) for MetS incidence. The incidence of MetS was examined across quartiles of FINDRISC, and a receiver operating characteristic (ROC) curve was plotted to assess the discrimination. At baseline and through follow-ups, participants underwent a standard 75 g 2-hour oral glucose tolerance test (OGTT). Data for determining FINDRISC were available from each participant. RESULTS: During 8,089 person-years of follow-up, 69 men and 209 women without MetS and diabetes at baseline subsequently developed MetS. The incidence of MetS was 31.4 per 1000 person-years in men and 35.5 in women. The FINDRSC at baseline was significantly associated with MetS evolution. Participants in the top quartile of FINDRISC were 4.4 times more likely to develop MetS than those in the bottom quartile (rate ratio 4.4; 95% CI 2.7-7.0). The area under the ROC curve was 65.0% (95% CI 61.3-68.7). CONCLUSION: The results of this study suggest that FINDRISC can be applied to detect MetS in a high-risk population.
OBJECTIVES: Traditionally, the Finnish Diabetes Risk Score (FINDRISC) questionnaire is a screening tool to estimate risk of type 2 diabetes. In this study, we evaluated the ability of FINDRISC to predict the development of the metabolic syndrome (MetS) in an Iranian population without diabetes and MetS. METHODS: A total of 1,010 first-degree relatives of consecutive patients with type 2 diabetes, 30-70 years old (274 men and 736 women), without diabetes and MetS, were examined and followed up over 8.0 ± 1.6 years (mean ± SD) for MetS incidence. The incidence of MetS was examined across quartiles of FINDRISC, and a receiver operating characteristic (ROC) curve was plotted to assess the discrimination. At baseline and through follow-ups, participants underwent a standard 75 g 2-hour oral glucose tolerance test (OGTT). Data for determining FINDRISC were available from each participant. RESULTS: During 8,089 person-years of follow-up, 69 men and 209 women without MetS and diabetes at baseline subsequently developed MetS. The incidence of MetS was 31.4 per 1000 person-years in men and 35.5 in women. The FINDRSC at baseline was significantly associated with MetS evolution. Participants in the top quartile of FINDRISC were 4.4 times more likely to develop MetS than those in the bottom quartile (rate ratio 4.4; 95% CI 2.7-7.0). The area under the ROC curve was 65.0% (95% CI 61.3-68.7). CONCLUSION: The results of this study suggest that FINDRISC can be applied to detect MetS in a high-risk population.
Authors: Trevor J Orchard; Marinella Temprosa; Ronald Goldberg; Steven Haffner; Robert Ratner; Santica Marcovina; Sarah Fowler Journal: Ann Intern Med Date: 2005-04-19 Impact factor: 25.391
Authors: Michael P Stern; Ken Williams; Clicerio González-Villalpando; Kelly J Hunt; Steven M Haffner Journal: Diabetes Care Date: 2004-11 Impact factor: 19.112
Authors: David W Dunstan; Paul Z Zimmet; Timothy A Welborn; Maximilian P De Courten; Adrian J Cameron; Richard A Sicree; Terry Dwyer; Stephen Colagiuri; Damien Jolley; Matthew Knuiman; Robert Atkins; Jonathan E Shaw Journal: Diabetes Care Date: 2002-05 Impact factor: 19.112
Authors: Richard K D Ephraim; Victor Boachie Owusu; Jephthah Asiamah; Arnold Mills; Albert Abaka-Yawson; Godsway Edem Kpene; Precious Kwablah Kwadzokpui; Samuel Adusei Journal: J Diabetes Metab Disord Date: 2020-10-08
Authors: Abraham S Meijnikman; Christophe E M De Block; An Verrijken; Ilse Mertens; Luc F Van Gaal Journal: Diabetol Metab Syndr Date: 2018-03-01 Impact factor: 3.320
Authors: Bernarda Sánchez-Jiménez; Gabriela Chico-Barba; Ana Lilia Rodríguez-Ventura; Reyna Sámano; Daniela Veruete-Bedolla; Rosa María Morales-Hernández Journal: Rev Lat Am Enfermagem Date: 2019-07-18